AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-85. **(Cancelled)**

86. **(Currently Amended)** A method for treating Parkinson's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Parkinson's disease in said subject is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ~~ICE inhibitors, neuroimmunophilis~~, N-acetylcysteine, antioxidants, lipoic acid, ~~cofactors,~~ riboflavin, and CoQ10, wherein said creatine compound has the formula:



and pharmaceutically acceptable salts thereof, wherein:

a) Y is $-CO_2H$;

b) A is selected from the group consisting of: C, CH, C_1-C_5alkyl, C_2-C_5alkenyl, C_2-C_5alkynyl, and C_1-C_5 alkoyl chain, each having 0-2 substituents which are selected independently from the group consisting of:

1) K, where K is selected from the group consisting of: C_1 -C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

2 -NH-M, wherein M is selected from the group consisting of: hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_1-C_4 alkoyl, C_3-C_4 branched alkyl, C_3-C_4 branched alkenyl, and C_4 branched alkoyl;

c) X is NR_1, wherein R_1 is selected from the group consisting of:

1) hydrogen;

2) K where K is selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

d) Z_1 and Z_2 are chosen independently from the group consisting of: -NHR_2, wherein R_2 is selected from the group consisting of:

1) hydrogen;

2) K, where K is selected from the group consisting of: C_1-C_6 straight alkyl; C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

3 a C_4-C_8 a-amino-carboxylic acid attached via the w-carbon; and

4 B, wherein B is selected from the group consisting of: -CO_2H, -NHOH, -SO_3H, and -NO_2, ~~wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl,~~ wherein B is optionally connected to the nitrogen via a linker selected from the group consisting of: C_1-C_2 alkyl, C_2 alkenyl, and C_1-C_2 alkoyl.

87-90. **(Cancelled)**

91. **(Previously Presented)** The method of claim 86 or 133, wherein said neuroprotective agent is a spin trap.

92. **(Cancelled)**

93. **(Currently Amended)** The method of claim 86 or 133, wherein said neuroprotective agent is ~~a cofactor for normal cellular metabolism~~ carnitine.

94. **(Cancelled)**

95. **(Previously Presented)** The method of claim 86 or 133, wherein said neuroprotective agent is an antioxidant.

96. **(Cancelled)**

97. **(Cancelled)**

98. **(Previously Presented)** The method of claim 86 or 133, wherein said neuroprotective agent is riboflavin.

99. **(Previously Presented)** The method of claim 86 or 133, further comprising administering at least one additional neuroprotective agent or creatine compound.

100. **(Previously Presented)** The method of claim 86 or 133, wherein said creatine compound is creatine.

101-107. **(Cancelled)**

108. **(Currently Amended)** A method for treating Huntington's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Huntington's disease is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ~~ICE inhibitors, neuroimmunophilis,~~ N-acetylcysteine, antioxidants, lipoic acid, ~~cofactors,~~ riboflavin, and CoQ10, wherein said creatine compound has the formula:



and pharmaceutically acceptable salts thereof, wherein:

a) $-CO_2H$;

b) A is selected from the group consisting of: C, CH, C_1-C_5alkyl, C_2-C_5alkenyl, C_2-C_5alkynyl, and C_1-C_5 alkoyl chain, each having 0-2 substituents which are selected independently from the group consisting of:

1) K, where K is selected from the group consisting of: C_1 -C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

2) -NH-M, wherein M is selected from the group consisting of: hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_1-C_4 alkoyl, C_3-C_4 branched alkyl, C_3-C_4 branched alkenyl, and C_4 branched alkoyl;

c) X is NR_1, wherein R_1 is selected from the group consisting of:

1) hydrogen;

2) K where K is selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

d) Z_1 and Z_2 are chosen independently from the group consisting of: $-NHR_2$, wherein R_2 is selected from the group consisting of:

1) hydrogen;

2) K, where K is selected from the group consisting of: C_1-C_6 straight alkyl; C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

3) a C_4-C_8 a-amino-carboxylic acid attached via the w-carbon; and

4) B, wherein B is selected from the group consisting of: -CO_2H, -NHOH, -SO_3H, and -NO_2, ~~wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl,~~ wherein B is optionally connected to the nitrogen via a linker selected from the group consisting of: C_1-C_2 alkyl, C_2 alkenyl, and C_1-C_2 alkoyl.

109-112. **(Cancelled)**

113. **(Previously Presented)** The method of claim 108 or 134, wherein said neuroprotective agent is a spin trap.

114. **(Cancelled)**

115. **(Currently Amended)** The method of claim 108 or 134, wherein said neuroprotective agent cofactor is ~~a cofactor for normal cellular metabolism~~ carnitine.

116. **(Cancelled)**

117. **(Previously Presented)** The method of claim 108 or 134, wherein said neuroprotective agent is an antioxidant.

118. **(Cancelled)**

119. **(Cancelled)**

120. **(Previously Presented)** The method of claim 117, wherein said neuroprotective agent is riboflavin.

121. **(Previously Presented)** The method of claim 108 or 134, further comprising administering at least one additional neuroprotective agent or creatine compound.

122. **(Previously Presented)** The method of claim 108 or 134, wherein said creatine compound is creatine.

123-132. **(Cancelled)**

133. **(Currently Amended)** A method for treating Parkinson's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Parkinson's disease in said subject is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ~~ICE inhibitors, neuroimmunophilis,~~ N-acetylcysteine, antioxidants, lipoic acid, ~~cofactors,~~ riboflavin, and CoQ10, wherein said creatine compound is selected from the group consisting of:


,

,

,

,

,

,

,

, and pharmaceutically acceptable salts thereof.

134. **(Currently Amended)** A method for treating Huntington's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Huntington's disease is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ~~ICE inhibitors, neuroimmunophilis,~~ N-acetylcysteine,

antioxidants, lipoic acid, ~~cofactors,~~ riboflavin, and CoQ10, wherein said creatine compound is selected from the group consisting of:


,

,

,

,

,

,

, and pharmaceutically acceptable salts thereof.